1 |
Actemra, mra |
- |
- |
- |
- |
107 [1] 107 💬 |
2 |
Mra |
- |
- |
- |
- |
046 [2] 46, 107 💬 |
3 |
Mra (actemra) |
- |
- |
- |
- |
107 [1] 107 💬 |
4 |
Mra (tocilizumab) |
Tocilizumab |
[1] D02596 D02596 💬 |
IL6R [1] IL6R 💬 |
Coronavirus disease - COVID-19 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 [2] 46, 107 💬 |
5 |
Mra 003 us |
- |
- |
- |
- |
049 [1] 49 💬 |
6 |
Mra(tocilizumab) |
Tocilizumab |
[1] D02596 D02596 💬 |
IL6R [1] IL6R 💬 |
Coronavirus disease - COVID-19 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
046 [2] 46, 107 💬 |
7 |
Mra, actemra |
- |
- |
- |
- |
046 [2] 46, 107 💬 |
8 |
Mra-sc |
- |
- |
- |
- |
046 [1] 46 💬 |
9 |
Tocilizumab (mra-sc) |
Tocilizumab |
[1] D02596 D02596 💬 |
IL6R [1] IL6R 💬 |
Coronavirus disease - COVID-19 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
040 [1] 40 💬 |